証拠の質 4.88/5
8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。
- D1 出典への根拠
- 5/5
- D2 出典の権威性
- 5/5
- D3 算術
- 5/5
- D4 不確実性
- 4/5
- D5 範囲
- 5/5
- D6 文章
- 5/5
- D7 認識の誠実性
- 5/5
- D8 注意事項の完全性
- 5/5
● あなたの要因 — このリスクをクリック ▾ して表示
- あなたの要因
認知リスク
膵臓がんは、一般の人々のがんに関する心的モデルの中で珍しい位置を占めています。大半の読者は、これを実数で最も一般的な死因のうちに位置付けません(正しくも——そうではないからです)が、大半の読者はこれを「悪いもの」、つまり聞きたくない診断として分類します。その直感はおおよそ正しいのです。膵臓がんは、肺がん、大腸がん、肝臓がん、胃がん、乳がんよりも毎年少ない人を死に至らしめますが、診断された人々のうちはるかに大きな割合を死に至らしめます。五年相対生存率は米国で約13%、世界で12%未満であり、一般的な固形腫瘍の中で最悪です。「膵臓」という言葉に付随する恐怖は、真に厳しい致死率に対する合理的に調整された反応です。
概算: 米国成人の50%ががんになることを非常にまたはある程度心配している(Gallup、全部位);膵臓がんは、罹患率が低いにもかかわらず最も致死性の高いサブタイプとして広く認識されている
出典: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
実際のリスク
世界で年間約467,000件の膵臓がん死亡(新規症例約511,000件)
世界全体、全年齢、膵臓がんのみ
計算を表示
IARC GLOBOCAN 2022の世界の膵臓がんの見出しから始めます:2022年に世界で500,000件を超える新規症例と470,000件近い死亡があり、膵臓がんは12番目に多いがんでありながら、がん死因としては6番目に多く——この順位の不一致は、侵攻性の致死率を直接反映しています。世界の成人人口(18歳以上)約5.5 billionにわたって分散すると、年間約467,000件の膵臓がん死亡は、成人10,000人あたり年間約0.85件です。単純な60年の複利計算では約0.5%となりますが、年齢加重(膵臓がんの死亡率は60〜80歳の帯に大きく集中しており、成人期の最後の三分の一におけるハザードは集団平均の数倍高い)により、現実的な世界の成人生涯の数字は約0.8%まで引き上げられます。ACSによる米国の直接的な数字はより高くなっています:膵臓がんを発症する生涯リスクは男性で約56分の1、女性で約60分の1であり、5年相対生存率が約13%であることから、含意される長期の致死率は約85-90%となり、米国の生涯膵臓がん死亡確率は約1.4%(約71分の1)となります。見出しの数字は0.008(約125分の1)で、世界の成人から米国の成人までの範囲をカバーするために0.005-0.015の不確実性の幅があります。範囲はがん生涯の親項目に合わせて世界の成人生涯であり、regional_breakdownの米国の行が幅の上限を固定しています。
注意事項: 膵臓がんは、罹患率ではなく致死率が要となる数字である項目です。米国の生涯*罹患率*はSEERによると約1.6%で——乳がん、前立腺がん、肺がん、大腸がんより大幅…
膵臓がんは、罹患率ではなく致死率が要となる数字である項目です。米国の生涯*罹患率*はSEERによると約1.6%で——乳がん、前立腺がん、肺がん、大腸がんより大幅に低いです。膵臓がんを際立たせているのは、診断から死亡までの圧縮です。同じ年の米国の死亡約52,000件に対して米国の診断約67,000件は、死亡対症例の比率が0.8に近づき、これは一般的ながんの中で最も高く、5年相対生存率13%は固形腫瘍としてSEERシステムの中で最も低いものです。その圧縮の背後にある生物学は構造的なものです。膵臓は胃の後ろの後腹膜の深部に位置し、症状は曖昧で遅く、腫瘍の約12-15%のみが、5年生存率が44%に達する限局期に発見されます。現在、平均的なリスクの成人に対する有効な集団レベルのスクリーニングプログラムはありません——USPSTFは引き続き定期的なスクリーニングを推奨していません——なぜなら有病率が低すぎ、利用可能な検査は正味の害を回避するのに十分な特異性がないからです。監視画像診断は、限定された高リスク群にのみ推奨されます:遺伝性膵炎、家族性膵臓がんの血族、および特定の生殖細胞系列変異のキャリアです。2030年までに米国のがん死因の二番目になるという予測は、膵臓がんの転帰の悪化よりも、現在より大きいがんの治療の改善を反映しています。年齢標準化された膵臓がんの死亡率は、数十年にわたってほぼ横ばいです。
リスクはどう変わるか
見出しの数値は大きく異なる状況の平均です。シナリオや文脈による確率の違いは以下の通りです:
125分の1
~467,000 pancreatic cancer deaths/yr across ~8B people (IARC GLOBOCAN 2022); age-weighted adult lifetime figure
71分の1 · 1.4%
Derived from ~1.6% SEER lifetime incidence combined with ~85-90% long-run case-fatality; ~1 in 71
67分の1 · 1.5%
Incidence and mortality rates among the highest worldwide; Central and Eastern European countries sit at the top of the IARC pancreatic cancer ranking
333分の1
Lower incidence; confounded by competing mortality (infectious disease, maternal, injury) removing adults from the denominator before peak pancreatic-cancer-risk age
バーの長さと濃淡は、これらのシナリオを他のリスクとではなく、互いに比較して順位付けしたものです。正確な確率は各項目の横に表示されています。
関連するリスク
似たテーマの他のリスク — 関連する不安を探るために。
比較対象を選択
Pancreatic cancer kills close to 470,000 people a year worldwide per the IARC’s GLOBOCAN 2022 release, against more than 500,000 new cases — the 12th most common cancer globally but the 6th most common cause of cancer death. That ranking mismatch is the whole story. In the US, the American Cancer Society projects roughly 67,500 new pancreatic cancer diagnoses and 52,700 deaths in 2026: a deaths-to-cases ratio near 0.8, higher than any other common cancer. The lifetime risk of developing pancreatic cancer is ~1 in 56 for men and ~1 in 60 for women, and with SEER 5-year relative survival of 13.3% — the lowest of any common solid tumor — the implied US lifetime pancreatic-cancer-death probability is roughly 1 in 71, about 1.4%. Spread across a global adult window, the population figure is lower: roughly 1 in 125 lifetime for a generic adult alive today. Either way, pancreatic cancer kills fewer people each year than lung, colorectal, liver, stomach, or breast cancer — it just kills a much larger fraction of the people it diagnoses.
Why the case-fatality is so high comes down to anatomy and biology more than treatment failure. The pancreas sits deep in the retroperitoneum, symptoms are vague and late, and only about 12-15% of tumors are diagnosed at the localized stage, where 5-year survival reaches 44%. Regional disease drops survival to 17%; distant (metastatic) disease, which is how roughly half of cases present, sits at 3%. There is no effective population-level screening for average-risk adults. The US Preventive Services Task Force continues to recommend against routine screening because the prevalence is too low and the available imaging and blood-based tests are not specific enough to avoid a net harm from false positives and incidental findings. Surveillance imaging is reserved for defined high-risk groups — hereditary pancreatitis kindreds, familial pancreatic cancer kindreds, and carriers of germline BRCA2, Lynch syndrome, PRSS1, CDKN2A, and Peutz-Jeghers variants — where the baseline risk is high enough that the test characteristics land on the right side of the benefit-harm curve.
The trend paragraph is where pancreatic cancer does move around. Rahib and colleagues in Cancer Research projected in 2014 that pancreatic cancer will become the second leading cause of cancer death in the US by 2030, passing breast, prostate, and colorectal to sit behind only lung cancer. The rising relative ranking is not a story about deteriorating pancreatic outcomes — age-standardized pancreatic cancer mortality has been roughly flat for decades — but about improvements in treating the currently-larger cancers and about population ageing pulling more adults into the age window where pancreatic cancer hazard peaks. The short version is that the public intuition filed under “the bad one” is approximately calibrated: the raw count is smaller than the intuition probably suggests, but the conditional probability of dying once diagnosed is worse than any other common cancer, and the gap between those two numbers is the reason the word carries the weight it does.
関連する豆知識
世界の成人が膵臓がんで死ぬ生涯確率はおよそ1 in 125です。肺がんや大腸がんより死者は少ないものの、診断された人のうち命を落とす割合ははるかに大きく、5年生存率は約13%と、よくある固形がんで最悪です。
根拠台帳
以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。
1/5 件の出典が引用元と一字一句一致することを独立して検証済み
-
[1] International Agency for Research on Cancer (IARC) / World Health Organization — Pancreatic Cancer
Pancreatic Cancer- 統計値
More than 500,000 pancreatic cancer cases diagnosed in 2022 and almost 470,000 deaths globally; 12th most common cancer but 6th most common cause of cancer death; one of the cancer types with the least favourable prognosis- 抜粋
“"more than 500 000 people estimated to have been diagnosed with pancreatic cancer in 2022 [...] almost 470 000 deaths in 2022 [...] only the 12th most common cancer type globally [...] the sixth most common cause of cancer death [...] It is one of the cancer types with the least favourable prognosis." ”
- 出典データ
- 2024-04-04
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- GLOBOCAN 2022 headline used directly as the native number. ~467,000 annual global pancreatic cancer deaths across ~5.5 billion adults is ~0.85 per 10,000 adult-years. Age-weighted over a 60-year adult window — pancreatic cancer hazard in the 60s and 70s is several times the adult average — gives a lifetime adult-lifetime mortality near 0.008 (~1 in 125). The ranking mismatch (12th in incidence, 6th in mortality) is the core quantitative statement of the "diagnosis ≈ death" story and is used directly in the long-form body text.
- 独立性
- IARC GLOBOCAN is the upstream dataset used by WHO, ACS international comparisons, and the IHME Global Burden of Disease pancreatic cancer module. Treat this as the canonical global source; the SEER and ACS US numbers below are methodologically independent cross-checks.
-
[2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Pancreatic Cancer
Cancer Stat Facts: Pancreatic Cancer- 統計値
5-year relative survival 13.3% (2015-2021); ~1.6% of men and women will be diagnosed with pancreatic cancer at some point during their lifetime; estimated 67,440 new cases and 51,980 deaths in 2025; 3.3% of all new cancer cases; stage distribution at diagnosis is 15% localized, 28% regional, 51% distant, 5% unknown- 抜粋
“"5-Year Relative Survival: 13.3% [...] Approximately 1.6 percent of men and women will be diagnosed with pancreatic cancer at some point during their lifetime [...] Estimated New Cases in 2025: 67,440 [...] Estimated Deaths in 2025: 51,980 [...] 3.3% of all new cancer cases. [...] For pancreatic cancer, 15.4% are diagnosed at the local stage. [...] Stage Distribution (%): Localized 15 [...] Regional 28 [...] Distant 51 [...] Unknown 5." ”
- 出典データ
- 2025-04-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- SEER gives direct lifetime incidence of ~1.6% for the US population. With 5-year relative survival at 13.3% — the lowest of any common solid tumor — the implied long-run case-fatality is roughly 85-90%. 1.6% lifetime incidence × ~88% long-run case-fatality yields a US lifetime pancreatic-cancer-death probability of ~1.4% (~1 in 71), consistent with the ACS lifetime-risk page. The ratio of annual deaths (~52,000) to annual new cases (~67,000) is ~0.78 on a single-year basis, which understates the long-run case-fatality because most deaths occur outside the diagnosis year. This anchors the US row in the regional breakdown and the top of the Likelier uncertainty band. The same SEER page's stage-distribution table shows 51% of cases are diagnosed at the distant (metastatic) stage versus only 15% localized — the direct source for the body text's "roughly half of cases present" at the distant stage, and the diagnosis-time complement to the stage-conditional survival figures in the ACS survival-rates source below.
- 独立性
- SEER (NCI) and IARC GLOBOCAN (WHO) are methodologically independent compilation pipelines. SEER uses US vital registration and population-based cancer registries; IARC aggregates national registry data worldwide.
-
[3] American Cancer Society — Key Statistics for Pancreatic Cancer
Key Statistics for Pancreatic Cancer- 統計値
Lifetime risk of pancreatic cancer ~1 in 56 in men and ~1 in 60 in women; ~67,530 new cases and ~52,740 deaths projected for 2026 in the US; ~3% of US cancers but ~8% of US cancer deaths- 抜粋
“"The average lifetime risk of pancreatic cancer is about 1 in 56 in men and about 1 in 60 in women. [...] About 67,530 people (35,190 men and 32,340 women) will be diagnosed with pancreatic cancer. [...] About 52,740 people (27,230 men and 25,510 women) will die of pancreatic cancer." ”
- 出典データ
- 2026-01-16
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- ACS projects ~67,530 US new cases and ~52,740 US deaths in 2026 — a ratio of ~0.78 annual deaths to annual diagnoses, which is the single most compressed deaths-to-cases ratio of any common US cancer. The "about 3% of all cancers but about 8% of all cancer deaths" framing is used in the body text as the plain-English version of the GLOBOCAN "12th in incidence, 6th in mortality" ranking. The lifetime-risk-of- developing figures (~1 in 56 men, ~1 in 60 women) combined with the ~85-90% long-run case-fatality from SEER give the ~1.4% US lifetime pancreatic-cancer-death probability used as the US anchor.
- 独立性
- ACS Key Statistics and SEER Stat Facts share the same US vital registration and cancer registry upstream. Treat as a single institutional pipeline for the US-specific figures; the IARC source is the methodologically independent global cross-check.
-
[4] American Cancer Society — Survival Rates for Pancreatic Cancer
Survival Rates for Pancreatic Cancer- 統計値
5-year relative survival by stage (SEER 2015-2021): localized 44%, regional 17%, distant 3%, all stages combined 13%- 抜粋
“"Localized 44% [...] Regional 17% [...] Distant 3% [...] All SEER stages combined 13%." ”
- 出典データ
- 2025-03-14
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- Stage-conditional 5-year survival figures used in the long-form body text. The gap between localized (44%) and distant (3%) is roughly 15x, the largest stage-conditional survival gap of any common cancer in the SEER system. Combined with the fact that only about 12-15% of pancreatic cancers are diagnosed at the localized stage (per SEER staging distribution), the "no effective screening" story falls out arithmetically: the tumor is almost always metastatic or locally advanced at diagnosis.
- 独立性
- Draws on the same SEER staging distribution and relative survival pipeline as the SEER Stat Facts source above. Used as the stage- conditional cross-reference, not as an independent verification of the aggregate mortality figure.
-
[5] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM / Cancer Research — Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States 検証済み
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States- 統計値
Pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death in the US by 2030- 抜粋
“"pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030." ”
- 出典データ
- 2014-06-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- Rahib et al. 2014 is the widely cited source for the "second leading cause of US cancer death by 2030" projection used in the body text. The projected rise in ranking is driven almost entirely by improvements in treating the currently-larger cancers (breast, prostate, colorectal) and by population ageing, not by deteriorating pancreatic outcomes — age-standardized pancreatic cancer mortality has been roughly flat for decades. Used as the "trend" paragraph anchor, not as part of the headline probability calculation.
- 独立性
- Rahib et al. projects from SEER incidence and NCHS mortality data, so upstream is the same as the SEER/ACS sources. Independent analytically in the sense that it is a projection model rather than a retrospective count, but not an independent data pipeline.







